Publications

Sreerupa Challa, Shenghua Zhou, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Geeta Meher, Rayomand Gimi, Diane Schmidt, Dillon Cleary, Nezam Afdhal, and Radhakrishnan Iyer Preclinical Studies of SB 11285, a Novel STING agonist for Immuno-oncology June 7, 2017.
read abstract

Meleri Jones, Morven E. Cunningham, Peter Wing, Sampath DeSilva, Rupa Challa, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Radhakrishnan P. Iyer, Brent E. Korba, Nezam Afdhal, and Graham R. Foster. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. Journal of Medical Virology. 2017; 9999:1-9.
read article

Cybele C. García1, José R. Peña1, M. Laura Morell1, Sandra M. Cordo1, Sreerupa Challa2, Shenghua Zhou2, Anjaneyulu Sheri2, Seetharamaiyer Padmanabhan2, Geeta Meher2, Diane Schmidt2, Niraj K. Shil3, Meleri Jones4, Graham R. Foster4, Santanu Bose3, Nezam Afdhal2, Brent E. Korba5 and Radhakrishnan P. Iyer2.
(1) Laboratorio de Estrategias Antivirales- Laboratorio de Bioquímica y Biología del virus Junín, Universidad de Buenos Aires; (2) Spring Bank Pharmaceuticals, Inc., Milford, MA 01757; (3) Washington State University, Pullman, WA 99164; (4) The Liver Unit, Blizard Institute, Barts Health, Queen Mary University of London, UK; (5) Georgetown University Medical Center, Division of Molecular Virology and Immunology, Washington DC 20057. The STING Agonist SB 11285 is a Broad-spectrum Antiviral Agent May 23, 2017.
view poster

Sreerupa Challa1, Shenghua Zhou1, Anjaneyulu Sheri1, Samantha Delaney1, Rayomand Gimi1, Seetharamaiyer Padmanabhan1, Geeta Meher1, Diane Schmidt1, Dillon Cleary1, Santosh Khedkar2, Nezam Afdhal1, and Radhakrishnan Iyer1
(1) Spring Bank Pharmaceuticals, Inc., Milford, MA; (2) ChemBio Discovery Solutions, Lexington, MA. Novel Class of STING Agonists for Immuno-oncology March 23, 2017.
view poster

Shenghua Zhou1, Sreerupa Challa1, Anjaneyulu Sheri1, Geeta Meher1, Seetharamaiyer Padmanabhan1, Dillon Cleary1, Vishal Nair1, Rayomand Gimi1, Samantha Delaney1, Diane Schmidt1, Santosh Khedkar2, Nezam Afdhal1 and Radhakrishnan Iyer1
(1) Spring Bank Pharmaceuticals, Inc., Milford, MA; (2) ChemBio Discovery Solutions, Lexington, MA. Characterization of SB 11285 as a Novel STING Agonist for Immuno-oncology March 23, 2017.
view poster

Manasa Suresh1, Kyle E. Korolowicz1, Maria Balarezo1, Radhakrishnan P. Iyer2, Seetharamaiyer Padmanabhan2, Dillon Cleary2, Rayomand Gimi2, Anjaneyulu Sheri2,Changsuek Yon1, Bhaskar V. Kallakury3, Robin D. Tucker4, Nezam Afdhal2, Stephan Menne1
(1) Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, District of Columbia, United States of America, (2) Spring Bank Pharmaceuticals, Inc., Milford, Massachusetts, United States of America, (3) Department of Pathology, Georgetown University Medical Center, Washington, District of Columbia, United States of America, (4) Department of Comparative Medicine, Georgetown University Medical Center, Washington, District of Columbia, United States of America. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks January 5, 2017
read

Shenghua Zhou1, Sreerupa Challa1, Seetharamaiyer Padmanabhan1, Anjaneyulu Sheri1, Dillon Cleary1, Rayomand Gimi1, Geeta Meher1, Samantha Delaney1, Vishal Nair1, Diane Schmidt1, Santosh Khedkar2, Radhakrishnan Iyer1
(1) Spring Bank Pharmaceuticals, Inc., Milford, MA; (2) ChemBio Discovery Solutions, Lexington, MA.  Novel Dinucleotides that Activate cGAS- STING Signaling for Immuno-oncology October 22, 2016.
view poster

Kyle E. Korolowicz, Radhakrishnan P. Iyer, Stefanie Czerwinski, Manasa Suresh, Junming Yang, Seetharamaiyer Padmanabhan, Anjaneyulu Sheri, Rajendra K. Pandey, Jeffrey Skell, Judith K. Marquis, Bhaskar V. Kallakury, Robin D. Tucker, Stephan Menne Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B August 23, 2016.
read article

Carol A. Nelson4, Judith K Marquis1, Radhakrishnan P Iyer1, Nezam H. Afdhal1, Carol E. Green2, Anna Furimsky2, Patricia Byrge2, Mirza Jahic3, Mark Warren3, Jane Huang3, and Jon Mirsalis2
(1) Spring Bank Pharmaceuticals, Milford, MA; (2) SRI International, Menlo Park, CA; (3) Optivia Biotechnology Inc., Menlo Park, CA; (4) Independent Consultant, Chelmsford, MA. In vitro Metabolism, CYP Inhibitory Potential and Transport Studies of SB 9200 – A Novel Broad-Spectrum Antiviral Agent April 20, 2016.
view poster

Judith K Marquis1, Carol A. Nelson4, Nezam H. Afdhal1, Radhakrishnan P Iyer1, Carol E. Green2, Roger N. Hayes3, Lori Cochrane3, Ryan J. Anstatt3, and Jon Mirsalis2
(1) Spring Bank Pharmaceuticals, Milford, MA; (2) SRI International, Menlo Park, CA; (3) MPI Research, Mattawan, MI; (4) Independent Consultant, Chelmsford, MA. SB 9200, a Novel Antiviral Agent, Targets Liver after Oral Administration to Rats April 18, 2016.
view poster

Manasa Suresh1, Kyle Korolowicz1, Stefanie Czerwinski1, Radhakrishnan P Iyer2, Seetharamaiyer Padmanabahan2, Sreerupa Challa2, Shenghua Zhou2, Robin Tucker3, and Stephan Menne1
(1) Microbiology and Immunology, Georgetown Univ. Med. Center, Washington, DC., (2) Spring Bank Pharmaceuticals, Milford, MA; (3) Department of Comparative Medicine, Georgetown Univ. Med. Center, Washington, DC. Activation and Induction of Immune Response Genes RIG-1, STING, and NOD2 in Antiviral Activity of SB 9200 in the Woodchuck Model of Chronic Hepatitis B April 18, 2016.
view poster

Sreerupa Challa1, Anjaneyulu Sheri1, Seetharamaiyer Padmanabhan1, Brent. E. Korba2, Te-Hung Chang3, Niraj K. Shil4, Santanu Bose4, and Radhakrishnan P. Iyer1
(1) Spring Bank Pharmaceuticals, Inc., 113 Cedar Street, Milford, MA 01757; (2) Georgetown University Medical Center, Division of Molecular Virology and Immunology, Washington DC 20057; (3) University of Texas Health Sciences Center, San Antonio, TX 78229; (4) Washington State University, Pullman, WA 99164. PROPHYLACTIC AND THERAPEUTIC ANTI-RSV ACTIVITY OF SB 9200 – A NOVEL AGENT THAT ACTIVATES RIG-I AND NOD2 April 18, 2016.
view poster

Kyle Korolowicz1, Maria Balarezo1, Radhakrishnan Iyer2, Seetharamaiyer Padmanabhan2, Dillon Cleary2, Rayomand Gimi2, Anjaneyulu Sheri2, Manasa Suresh1, Changsuek Yon1, Robin Tucker3, Nezam Afdhal2, and Stephan Menne1, 1Microbiology and Immunology, Georgetown University Medical Center, Washington, DC, 2Spring Bank Pharmaceuticals, Milford, MA, 3Department of ComparaNve Medicine, Georgetown University Medical Center, Washington, DC, United States ANTIVIRAL EFFICACY AND HOST IMMUNE RESPONSE INDUCTION WITH SB 9200, AN ORAL PRODRUG OF THE DINUCLEOTIDE SB 9000, IN COMBINATION WITH ENTECAVIR IN THE WOODCHUCK MODEL OF CHRONIC HEPATITIS B April 15th, 2016.
view poster

Meleri Jones1, Morven E. Cunningham1, Peter Wing1, Sampath DeSilva1, Anjaneyulu Sheri2, Seetharamaiyer Padmanabhan2, Radhakrishnan P. Iyer2, Nezam Afdhal2 and Graham R. Foster1, 1The Liver Unit, Blizard Institute, Barts Health, Queen Mary University of London, UK
2Spring Bank Pharmaceuticals, Milford, MA, United States. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants April 14th, 2016.
view poster

Kumar Visvanathan2,1, Rosemary Millen2,1, Stuart K. Roberts4,5, Peter W. Angus6,2, Wendy Cheng8, Nada Farhat9, My My Trinh9, Radhakrishnan P. Iyer10,, Murray Barclay7, Alexander J. Thompson3,2, 1St Vincent’s Hospital Melbourne (Melbourne, Australia), 2Univeristy of Melbourne (VIC, Australia), 3St. Vincent’s Hospital (VIC, Australia), 4Alfred Hospital, Melbourne (VIC, Australia), 5Monash University ( VIC, Australia), 6Austin Hospital (VIC, Australia), 7Christchurch Hospital and University of Otago (Christchurch, New Zealand), 8Royal Perth Hospital (WA, Australia), 9Pharsight – A CertaraTM Company (Montreal, Canada), 10Spring Bank Pharmaceuticals (MA, United States). SB 9200 Shows Antiviral Activity Against HCV-RNA by Targeting Host Cytosolic Sensor Proteins RIG-I and NOD-2 to activate IFN signaling pathways. November 17th, 2015.
view poster

Kyle Korolowicz, Microbiology and Immunology, Georgetown University Medical Center, Washington, DC; Stefanie Czerwinski, Microbiology and Immunology, Georgetown University Medical Center, Washington, DC, Radhakrishnan Iyer, Spring Bank Pharmaceuticals, Milford, MA; Jeffrey Skell, Spring Bank Pharmaceuticals, Milford, MA; Junming Yang, Microbiology and Immunology, Georgetown University Medical Center, Washington, DC; Robin Tucker, Department of Comparative Medicine, Georgetown University Medical Center, Washington, DC, United States; and Stephan Menne, Microbiology and Immunology, Georgetown University Medical Center, Washington, DC. ANTIVIRAL EFFICACY AND INDUCTION OF HOST IMMUNE RESPONSES WITH SB 9200, AN ORAL PRODRUG OF THE DINUCLEOTIDE SB 9000, IN THE WOODCHUCK MODEL OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION. March 26th, 2015.
view poster

Alex J. Thompson, St Vincent’s Hospital, University of Melbourne (AUS);  Stuart Roberts, Alfred Hospital, Monash University (AUS); Wendy Cheng, Royal Perth Hospital (AUS); Peter Angus, Austin Hospital (AUS); Kumar Visvanathan, St Vincent’s Hospital, University of Melbourne (AUS); Radhakrishnan Iyer, Spring Bank Pharmaceuticals (USA); Murray Barclay, Christchurch Hospital, University of Otago (NZ) : SB 9200, a novel immunomodulator for patients with viral hepatitis: Phase I MAD study in patients with hepatitis C Virus (HCV) infection. April 4, 2015.
view poster

Poonam Advani, Blessy Joseph, Premlata Ambre, Raghuvir Pissurlenkar, Vijay Khedkar, Krishna Iyer, Satish Gabhe, Radhakrishnan P. Iyer & Evans Coutinho (2015): In silico optimization of pharmacokinetic properties and receptor binding affinity simultaneously: a ‘parallel progression approach to drug design’ applied to β-blockers, Journal of Biomolecular Structure and Dynamics, May 20, 2015,  DOI: 10.1080/07391102.2015.1033646
read

Coughlin, J. E., Pandey R. K., Padmanabhan, S. O’Loughlin, K.,Green,C. E., Mirsalis,J., Iyer, R. P. Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-HBV dinucleoside phosphorothioate. Drug Disposition and Metabolism (The American Society for Pharmacology and Experimental Therapeutics).  2012, 40, 970-981.

Ambre, P K., Pissurlenkar, R. R. S., Coutinho, E. C., Iyer, R. P. A unified model for Checkpoint-Kinase-1 inhibitors based on Docking, 3D-QSAR, and Pharmacophore modelingCan. J. Chem.  2012, 90, 675–692.

Rhee, S-W., Iyer, R. P., Coughlin, J., Padmanabhan, S., Malerich, J. P., Tanga, M. J. Synthesis of a 35S-labeled dinucleoside phosphorothioate prodrug, an orally bioavailable anti-HBV agent. J. of  Radiolabeled Compounds, 2012

Pissurlenkar, R.R.S., Khedkar, V. M., Iyer, R. P., Coutinho, E. Ensemble QSAR: A QSAR method based on conformational ensembles and metric descriptors. J. Comput. Chem. 2011, 32: 2204–2218.

Coughlin, J. E., Padmanabhan, S.,Zhang, G., Kirk, C. J., Govardhan,C. P., Brent E. Korba, B. E.,O’Loughlin, K.,Green,C. E., Mirsalis,J., Morrey,J. D., Iyer, R. P. Orally Bioavailable Anti-HBV Dinucleotide Acyloxyalkyl Prodrugs. Bioorg. Med. Chem. Lett. 2010, 20, 1783–1786.

Y. Y. Pedgaonkar, M. S. Degani, R. P. Iyer. Diversity Oriented, One-pot multi-component synthesis of substituted uracil derivatives. Molecular Diversity, 2010, 15, 263-7.

Pissurlenkar, R.R.S., Iyer, R. P., Coutinho, E. Force fields for Molecular Mechanics – Applications in Structure-based Drug Design, Current Medicinal Chemistry (invited review). Anti-infective Agents in Medicinal Chemistry, 2009, 8, 128-150.

Zubair, M. A., Iyer, R. P., Akamanchi, K. G., Degani, M. S., Coutinho, E. C. Synthesis of Bispyrrole Tetra Esters and Alcohols as Novel  Mimetics of the Anticancer Mitomycin. J. Het. Chem., 2010, 48, 38-49.

Verma, J., Malde, A., Khedkar, S., Iyer, R. P., Coutinho, E. Local Indices for Similarity Analysis (LISA) – a 3D-QSAR formalism based on local molecular similarity. J. Chem. Inf. Model. 2009, 49, 2695–2707.

Padmanabhan, S., Coughlin, J. E., Zhang, Z., Kirk, C., Iyer, R. P. Anti-HBV Nucleotide Prodrug Analogs: Synthesis, bioreversibility, and cytotoxicity studiesBioorg. Med. Chem. Lett. 2006, 1491-94.

Iyer, R. P., Coughlin, J. E., Padmanabhan, S. Rapid functionalization and loading of solid supports. Organic Preparations & Procedure International, 2005, 37: 205-212.

Iyer, R. P., Padmanabhan, S., Zhang, G., Morrey, J. D., Korba, B. E. Nucleotide analogs as anti-Hepatitis B virus agents. Current Opinion in Pharmacology, 2005, 5: 520-528

Iyer, R. P., Padmanabhan, S. Microwave-assisted functionalization of solid supports for rapid loading of nucleosides. Current Protocols Unit 3.13, (Beaucage et al Eds,) John Wiley and Sons, Current Protocols Unit 3.13, (Beaucage et al Eds,) John Wiley and Sons, 2005.

Padmanabhan, S., Coughlin, J. E., Iyer, R. P. Microwave-assisted functionalization of solid supportsApplication in the rapid loading of nucleosides on controlled-pore-glass (CPG). Tetrahedron Lett. , 2005, 46, 343-347.

Iyer, R. P., Jin, Y., et al., Phosphorothioate Di- and Tri-nucleotides as a novel class of anti-HBV agents. Antimicrob. Agents Chemother., 2004, 48(6): 2199 – 2205.

Iyer, R. P., Roland A., et al., Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother., 2004, 48(6): 2318-20.

Iyer, R. P.; Marquis, J., Bonnez, W.  ORI-1001: Anti-papilloma virus oligonucleotide. Drugs of the Future, 2002, 27:546-557.

Iyer, R. P. Small molecule libraries based on Nucleic acid-based scaffold: A novel approach to antiviral discovery. ACS Medicinal chemistry symposium on antiviral therapeutics, Boston, 2002.

Iyer, R. P., Pandey, R., Kuchimanchi, S. RNA interference: An exciting new approach for target validation, gene expression analysis and therapeutics. Drugs of the Future, 2003, 28, 51-59. 

Xiao, Y.; Roland, A.; Jin, Y.; Iyer, R. P.  A novel linker for the solid-phase synthesis of a library of 3′-thiophosphorylated dinucleotides.  Tetrahedron Letters. 2001; Vol. 42 (Pgs. 3669-3672).

Jin, Y., Chen, X., C.T., M., Roland, A., Korba, B., Mounir, S., Iyer, R.P.  Parallel solid-phase synthesis of nucleoside phosphoramidate libraries.  Bioorganic Med Chem Letters. 2001.  Vol.  11.  No. 16. (Pgs. 2057-60).

Jin, Y.; Roland, A.; Zhou, W.; Fauchon, M.; Lyaku, J.; Iyer, R.P.  Synthesis and antiviral evaluation of nucleic acid-based (NAB ™) libraries.  Bioorganic and Medicinal Chemistry Letters.  2000; Vol. 10/17 (Pgs. 1921-1925).

Zhou, W., Upendran, S., Roland, A., Iyer, R.P. Nucleotide libraries as a source of biologically relevant chemical diversity:  solution-phase synthesis.  Bioorganic Medicinal Chemistry Letters.  2000; Vol.  10.  No. 11 (Pgs. 1249-52).

Zhou, W.; Roland, A.; Jin, Y.; Iyer, R.P. Nucleic acid-based scaffold (NAB) combinatorial libraries:  A novel source of chemical diversity.  Abstracts of Papers American Chemical Society.  2000; Vol. 220 – Part 1.

Iyer, R. P. Oligonucleotide analogs as potential therapeutics:  Challenges and prospects.  Abstracts of Papers American Chemical Society. 2000; Vol. 219 No. 1-2.

Iyer, R. P.; Jin, Y.; Roland, A.; Zhou, W. Combinatorial synthesis using nucleic acid-based (NABTM) scaffold:  Parallel solid-phase synthesis of nucleotide libraries.  Tetrahedron Letters.  2000; Vol. 41, No 4. (Pgs. 441-445).

Iyer, R. P. Nucleobase protection of deoxyribo- and ribo-nucleosides, In Current Protocols in Nucleic acids chemistry. John Wiley Publishers.

Iyer, R. P., Beaucage, S. L.   Oligonucleotide synthesis.  In: Comprehensive Natural Products. Elsevier Science.  1999; Vol. 7.  (Pgs.  105-152).

Iyer, R. P., Roland, A., Zhou, W., Ghosh, K.  Modified Oligonucleotides – syntheses, properties, and applications.  Curr.  Opin.  Mol.  Ther. 1999; Vol. 1., No 3.  (Pgs.  344-358).

 

Conference Abstracts 

R. P. Iyer, J. E. Coughlin, S. Padmanabhan,B. E. Korba, S. Myong, B. Tennant, and J. D. Morrey. Nucleotide Analogs That Induce Cellular Production of Antimicrobial Proteins. International Conference of Antiviral Research, San Francisco, 2010.

R. P. Iyer, J. E. Coughlin,S. Padmanabhan, B. E. Korbaand S. Myong. Activation of Retinoic Acid inducible Gene (RIG-I) by Nucleotide Analogs – A Potential Novel Mechanism for Antiviral Discovery. International Conference of Antiviral Research, San Francisco, 2010.

S. Padmanabhan,J. E. Coughlin, C. J. Kirk, R. P. Iyer,B. E. Korba, K. O’Loughlin, C. E. Green, J. Mirsalis, and John D. Morrey. Orally Bioavailable Anti-HBV Dinucleotide Acyloxyalkyl Prodrugs. International Conference of Antiviral Research, San Francisco, 2010.

K. O’Loughlin, L. Tang, R. P. Iyer, A. Furimsky, S. Rhee, A. Ta, L. Rausch, J. E. Coughlin, S. Padmanabhan, J. Marquis, C. E. Green, and J. Mirsalis. Pharmacokinetics and Distribution of SB 9002-1 Pro-Drug for Hepatitis Treatment. Society of Toxicology Meeting, 2010, San Francisco, 2010.

S. Padmanabhan, J. E. Coughlin, G. Zhang, C. J. Kirk, and R. P. Iyer. Anti-HBV Nucleotide Prodrug Analogs: Synthesis, Bioreversibility, and Cytotoxicity Studies. International Conference on Antiviral Research, CA, 2007.

R. P. Iyer, S. Padmanabhan, J. Coughlin, G. Zhang, C. Kirk,  B. Korba and J. D. Morrey. Initial pharmacodynamic Evaluation of Orally Bioavailable Prodrugs of SB-9000, A novel anti-HBV agent. International Conference on Antiviral Research, CA, 2007.

R. P. Iyer, ,S. R. Shastri,  S. A. Guhagarkar,R. Mulherkar,G. V. Joshi,  S. Padmanabhan,  J. E. Coughlin,  and P. V. Devarajan. Sublingual Delivery of an Anti-HBV Dinucleoside Phosphorothioate analog. International Conference on Antiviral Research, CA, 2007.

Iyer, R. P., S. Padmanabhan, J. Coughlin, C. Kirk, J. Morrey, and B. Korba. The dinucleotide SB-9000 as a novel anti-HBV agent – In vitro and In vivo studies. International Conference on the Molecular Biology of Hepatitis viruses, Woods Hole, October 2004.

S. Padmanabhan, R. P. Iyer, G. Zhang, and J. E. Coughlin. Microwave-assisted functionalization and loading of nucleosides on solid supports, American Chemical Society meeting. NERM 2005.